• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Taiwan·Healthcare·6539.TWO
Share

DV Biomed Co., Ltd. Stocks

NT$ 40Last Updated 28.07.2026

Issuer Rating

3/7
Performance

Favourable

Risk

High

Recommendation

Sell

Market Cap

NT$ 25.83M

NT$ 40
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Slightly undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

DV Biomed Co., Ltd. is engaged in the creation, production, and international sale of high-quality, medical-grade dermatological products. The company also extends its services to include wellness and weight management programs, and operates as a distributor for professional aesthetic fillers and advanced medical beauty devices. Complementing these offerings, DV Biomed supplies health-focused food items, such as functional light and energy drinks, alongside a range of facial care and broader beauty solutions. The company was established in 2011 and operates from its headquarters in Taipei, Taiwan.

Company Valuation

Slightly undervalued
5/7

Based on key historical and expected multiples, the stock is slightly undervalued relative to its peers. Specifically, the stock is overvalued on EV/EBITDA, reasonably pr

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

30.07.2026 02:31

The Nasdaq 100 Index closed the trading session in correction territory

30.07.2026 02:03

Microsoft Shares Rise After Earnings Report: Cloud Business Posts Best Growth Since 2022

30.07.2026 01:26

Yields on long-term U.S. Treasury bonds have reached their highest level since 2007

30.07.2026 01:20

Meta's earnings fell short of Wall Street's expectations. Its stock fell 6%.

30.07.2026 00:34

A War Between the U.S. and Iran Could Drag On for Several Months — Bloomberg

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026